2018 Documentation Drug Pricing 
FDA Law Blog: Biosimilars
JUNE 16, 2023
Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.
Safe Biologics
FEBRUARY 1, 2024
In 2018, the project was put on hold for data gathering. Over the years, the WHO has attempted to evaluate the BQ: a provisional implementation of the programme was suggested in 2016, and in 2017 a pilot BQ project was discussed. The ASBM would be interested in knowing the status of these approaches.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 6, 2023
Last week, Novartis announced plans to pay $245 million to end a pay-for-delay legal battle that started in 2018. In this most recent settlement, the drug company faced allegations of colluding with the generics company Par Pharmaceuticals to violate antitrust laws. Gilenya is an oral medication for multiple sclerosis.
Proxsys Rx
APRIL 19, 2024
In response, The Centers for Medicare & Medicaid Services ( CMS ) issued a proposed remedy for covered entities whose 340B payments were wrongly reduced in calendar years 2018-22. The ruling is an estimated 19,247 words long, or just over 37 pages, printed in single-spaced 10-point Arial.
pharmaphorum
JUNE 10, 2021
Against this backdrop, there has been substantial public debate about rising drug prices forced on consumers, including the trite notion that pharmaceutical companies are being “greedy” and seeking to price-gouge the public. The truth about rising drug prices is more nuanced and merits exploration.
Expert insights. Personalized for you.
45 
Let's personalize your content